Clinical Trials Logo

Filter by:
NCT ID: NCT04245839 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

TRANSCEND FL
Start date: July 14, 2020
Phase: Phase 2
Study type: Interventional

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: - Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; - Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29; - Posttreatment, which includes follow-up assessments for disease status and safety for 5 years.

NCT ID: NCT04244890 Completed - Infant, Newborn Clinical Trials

Feasibility of Uninterrupted Infant Respiratory Support Treatment

FUIRST
Start date: February 21, 2020
Phase:
Study type: Observational

Feasibility study of a simplified respiratory support system for newborn infants

NCT ID: NCT04244617 Completed - Mental Disorder Clinical Trials

Peer-supported Internet Mediated Psychological Treatment

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the effect and experience of peer-support in internet mediated ACT (Acceptance and Commitment therapy) in an explorative pilot study with mixed method design conducted in primary care. Peer-supporters are certified support persons with personal experience of mental health problems and the process of rehabilitation, which becomes professionally active in care and support to patients in their recovery

NCT ID: NCT04243005 Recruiting - Glioblastoma Clinical Trials

Supramarginal Resection in Glioblastoma

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is the most common subtype and unfortunately also the most aggressive subtype with median survival in population based cohorts being only 10 months. Extensive surgical resections followed by postoperative fractioned radiotherapy and concomitant and adjuvant temozolomide prolong survival and is the standard treatment. The investigators think there is significant potential in individualized surgical decision-making in glioblastoma management. The idea that some patients are amendable to radical surgery, while others should be treated more conservatively, is not controversial in other fields of oncology. The current concept in all patients with glioblastoma is "maximum safe resection of the contrast enhancing tumor", but this may in selected cases be extended to simply "maximum safe resection" tailored to the patient and extent of disease at hand. Densely proliferating tumor cells have been found from at an average of 10 mm beyond the margins of contrast enhancement in high-grade gliomas. There are now several case series, using various definitions of supramarginal resection, but they have in common that they report a benefit of resection with a margin. This potential benefit also comes together with an associated neurological risk, making this approach unethical and simply not feasible in the patients with glioblastoma as a whole. Objective of this study is: To investigate if resection with a margin, that is significantly beyond the radiological contrast enhancement, improves survival in selected patients with glioblastoma.

NCT ID: NCT04242329 Withdrawn - Surgery Clinical Trials

Surgery of Melanoma Metastases After Systemic Therapy

SUMMIST
Start date: March 11, 2021
Phase: Phase 2
Study type: Interventional

To evaluate if surgical removal of residual disease adds benefit in stage IV melanoma patients with partial response or stable disease after a minimum 9 months of first-line PD-1 inhibition. Primary endpoint: Disease-free survival (DFS) at 12 months.

NCT ID: NCT04241068 Active, not recruiting - Alzheimer's Disease Clinical Trials

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Start date: March 2, 2020
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).

NCT ID: NCT04241003 Completed - Clinical trials for Spinal Cord Injuries

Effects of the SmartDrive on Mobility, Activity and Shoulder Pain Among People With SCI Using Manual Wheelchairs

Start date: June 11, 2019
Phase: N/A
Study type: Interventional

This is a prospective study of manual wheelchair users with spinal cord injury (SCI). The users will be their own controls. The primary purpose of the study is to evaluate the ability of the power assist device SmartDrive to increase the ability to be mobile.

NCT ID: NCT04240262 Recruiting - Uterine Fibroid Clinical Trials

Microwave Ablation for Leiomyoma

MYOMIC2
Start date: January 20, 2020
Phase:
Study type: Observational

This prospective observational study aims to evaluate the effectiveness and acceptability of percutaneous or vaginal ultrasound guided microwave ablation for the treatment of symptoms related to uterine fibroids. We will include 200 women.

NCT ID: NCT04240249 Completed - Clinical trials for Problems With Self-assertiveness

Constructive Self Assertiveness Via the Internet

R2
Start date: February 1, 2020
Phase: N/A
Study type: Interventional

Some people have problems with self-assertiveness. That can have negative impact on their lives. This study will test a constructive self-assertiveness intervention program delivered online. In addition, the relative effect of guidance during the intervention will be investigated. In a randomized controlled trial three groups will be compared: 1. constructive self-assertiveness with guidance 2. constructive self-assertiveness without guidance 3. Waitlist control

NCT ID: NCT04239690 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

Preservation of Blood in Extremely Preterm Infants

LIM
Start date: March 15, 2020
Phase: N/A
Study type: Interventional

Current clinical protocols for blood sampling and analyses in extremely preterm infants rely on an infrastructure adapted to and developed for adult medicine. Excessive blood sampling volumes and the resulting loss of fetal blood components are related to neonatal morbidity. This randomised trial aims to provide evidence that preservation of blood using micro-methods results in decreased morbidity and increased quality of life in extremely preterm infants.